Establishing trust through thought leadership is no longer optional in today’s cautious biopharma market. This whitepaper will show leaders how strategic insights and targeted outreach can turn ...

Skysona can now only be used in patients with cerebral adrenoleukodystrophy who have no available treatment alternatives or ...

Gray Delany was pushed out due to disagreements with other top officials over how the Department of Health and Human Services ...

An interview with Philip Vanek, chief commercialization officer of the International Society for Cell & Gene Therapy (ISCT), ...

In the wake of multiple patient deaths from liver injuries related to Sarepta Therapeutics’ AAV gene therapy platform, some ...

The recent announcement of RFK Jr.’s termination of mRNA vaccine contracts is the latest effort to undermine this promising ...

Here are five oral obesity candidates that, according to Mizuho’s Graig Suvannavejh, could change the weight loss game.

Phase III data show Hernexeos can elicit a confirmed objective response rate of 48% in patients with HER2-mutated NSCLC who had previously been treated with a directed antibody-drug conjugate.

After exiting the FDA less than two weeks ago for unclear reasons, Vinay Prasad is once again director of the Center for ...

Arguably the FDA’s most anticipated decision this month is for a subcutaneous induction formulation of Biogen and Eisai’s ...

Eli Lilly’s orforglipron cut body weight to a lesser extent than rival Novo Nordisk’s semaglutide, falling into analysts’ ...

Strand Therapeutics' lead asset is STX-001, an intra-tumor self-replicating mRNA therapy that carries a payload expressing ...